ArticleCancer cell international2026
Targeted radio-thermo dual sensitizer magnetic gold core-shells nanoparticles enhance radioresistant glioblastoma via promoting apoptosis and ROS generation.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
MAIN
objectiveThis study aims to evaluate the therapeutic potential of targeted Fe3O4@Au/FA core-shell nanoparticles as dual sensitizers in enhancing radiotherapy and hyperthermia for C6 glioma cancer cells, minimizing off-target effects. The investigation focuses on the efficacy of this combination therapy in promoting apoptosis and generating reactive oxygen species (ROS).
methodsThe Fe3O4@Au/FA nanoparticles were synthesized and characterized using dynamic light scattering (DLS), transmission electron microscopy (TEM), and scanning electron microscopy (SEM) to confirm their size, zeta potential, and morphology. Fourier-transform infrared spectroscopy (FTIR) was used to analyze the functional groups on the nanoparticle surface. The cytotoxicity of the nanoparticles was assessed through the MTT assay on OLN-93 and C6 glioma cells, and cellular uptake was quantified via inductively coupled plasma optical emission spectrometry (ICP-OES). Ex vivo biocompatibility was evaluated with hemolysis tests and measurements of liver enzymes, urea, and creatinine. Heat generation was monitored during exposure to alternating magnetic fields (AMF) to calculate cumulative equivalent minutes (CEM). The therapeutic effects were evaluated using colony formation assays (CFA) for plating efficiency (PE) and survival fraction (SF) calculation. Flow cytometry was utilized to quantify apoptosis and necrosis, while intracellular ROS levels were measured with the DCFH-DA assay following combined treatments with varying doses of ionizing radiation (0–8 Gy).
resultsCharacterization confirmed the nanoparticles’ spherical morphology, with an average size of 40.8 ± 2.8 nm and a negative zeta potential of -19.93 mV. Ex vivo biocompatibility tests demonstrated that the nanoparticles exhibit good compatibility, suggesting minimal adverse effects on biological systems. ICP-OES confirmed effective cellular uptake. CFA revealed significant decreases in PE and SF for combined therapies. Flow cytometry showed enhanced apoptosis and necrosis in combined treatment groups (p < 0.01). Furthermore, ROS levels increased significantly with the maximum radiation dose in the combined treatment (p < 0.0001), highlighting the nanoparticles’ effectiveness in promoting therapeutic responses against glioma cells.
conclusionOur magnetic gold core-shell nanoparticles demonstrate good biocompatibility and effective tumor uptake, enhancing radiotherapy and hyperthermia for C6 glioma treatment. These findings highlight their potential for improving treatment outcomes through enhanced apoptosis and ROS generation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.